Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
119.00
+1.47 (1.25%)
Jan 22, 2026, 2:58 PM EST - Market open
Revolution Medicines Employees
Revolution Medicines had 809 employees as of September 30, 2025. The number of employees increased by 319 or 65.10% compared to the same quarter last year.
Employees
809
Change
319
Growth
65.10%
Revenue / Employee
n/a
Profits / Employee
-$1,187,859
Market Cap
23.01B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 809 | 319 | 65.10% |
| Jun 30, 2025 | 700 | 257 | 58.01% |
| Mar 31, 2025 | 616 | 205 | 49.88% |
| Dec 31, 2024 | 534 | 156 | 41.27% |
| Sep 30, 2024 | 490 | 152 | 44.97% |
| Jun 30, 2024 | 443 | 151 | 51.71% |
| Mar 31, 2024 | 411 | 152 | 58.69% |
| Dec 31, 2023 | 378 | 132 | 53.66% |
| Sep 30, 2023 | 338 | 99 | 41.42% |
| Jun 30, 2023 | 292 | 80 | 37.74% |
| Mar 31, 2023 | 259 | 58 | 28.86% |
| Dec 31, 2022 | 246 | 58 | 30.85% |
| Sep 30, 2022 | 239 | 77 | 47.53% |
| Jun 30, 2022 | 212 | 62 | 41.33% |
| Mar 31, 2022 | 201 | 70 | 53.44% |
| Dec 31, 2021 | 188 | 63 | 50.40% |
| Sep 30, 2021 | 162 | 45 | 38.46% |
| Jun 30, 2021 | 150 | 44 | 41.51% |
| Mar 31, 2021 | 131 | 31 | 31.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 11,000 |
| BioNTech SE | 6,772 |
| Moderna | 5,800 |
| Genmab | 2,681 |
| Incyte | 2,617 |
| Insmed | 1,271 |
| Ascendis Pharma | 1,017 |
| Roivant Sciences | 750 |
RVMD News
- 9 days ago - Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 13 days ago - Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion - WSJ
- 13 days ago - Revolution Medicines: "Strong Buy" As Acquisition Prospects Continue To Circle - Seeking Alpha
- 13 days ago - Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. - Barrons
- 13 days ago - Merck in talks to buy biotech Revolution Medicines, FT reports - Reuters
- 14 days ago - Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib - GlobeNewsWire
- 14 days ago - AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. - Barrons
- 15 days ago - AbbVie in talks to buy biotech Revolution Medicines, WSJ reports - Reuters